Free tool
FAERS Monitor: Cis-Mdp
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018124 or its brand name (Cis-Mdp, Technetium Tc-99m Medronate Kit). Reports on generic versions are filed under their own applications.
Reports
4
Serious
1
25% of reports
Hospitalization
0
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pruritus2
- erythema1
- hypersensitivity1
- palpitations1
- rash1
- throat tightness1
- ulcer1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1 |
| 2015 | 3 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,155 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ulcer | 1 | 330.6 | 60.5 | 82 |
| throat tightness | 1 | 194.4 | 35.6 | 48 |
| palpitations | 1 | 44.9 | 8.2 | 10 |
| hypersensitivity | 1 | 28.3 | 5.2 | 6 |
| pruritus | 2 | 27.4 | 10.3 | 28 |
| erythema | 1 | 25.6 | 4.7 | 5 |
| rash | 1 | 12.1 | 2.2 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.